|
|
|
| Efficacy of Intravitreal Injection of Ranibizumab on Neovascular Age-Related Macular Degeneration and Its Effects on Serum CRP VEGF Intraocular Pressure and Visual Acuity |
| HAN Song |
| The Fourth People's Hospital of Shenyang, Liaoning Shenyang 110031, China |
|
|
|
|
Abstract Objective: To investigate the efficacy of intravitreal injection of Ranibizumab in the treatment of neovascular age-related macular degeneration (nAMD) and its effects on serum C-reactive protein (CRP), vascular endothelial growth factor (VEGF), intraocular pressure and visual acuity of patients.Methods: Seventy-four patients with nAMD in our hospital were selected as the research subjects, and they were categorized as the Ranibizumab group and the Conbercept group with random number table method, with 37 cases in each group.The two groups were treated by intravitreal injection.The visual acuity [best corrected visual acuity (BCVA)], central retinal thickness (CRT), intraocular pressure and levels of serum CRP and VEGF before treatment and 4 weeks and 12 weeks after treatment and choroidal neovascularization (CNV) leakage at 12 weeks after treatment were compared between the two groups, and the clinical efficacy was evaluated, and the occurrence of complications were recorded during treatment.Results: There was no significant difference in intraocular pressure before and after treatment between the groups and within the groups (P>0.05).Comparison of visual acuity, CRT, serum CRP and VEGF before and after treatment in the two groups all showed before treatment> at 4 weeks after treatment>at 12 weeks after treatment (P<0.05).The CRT, serum CRP and VEGF in Ranibizumab group 4 and 12 weeks after treatment were lower than those in Conbercept group (P<0.05).There was no significant difference in visual acuity between the two groups 4 and 12 weeks after treatment (P>0.05).There were no significant differences in clinical efficacy and occurrence of complications during treatment between the two groups (P>0.05).Conclusion: In the case of intravitreal injection for nAMD, the efficacy and safety of Conbercept are comparable to those of Ranibizumab, but Ranibizumab has significant advantages in improving CRT and reducing expressions of CRP and VEGF, and it has high clinical application value.
|
|
|
|
|
|
[1] McGuinness MB,Finger RP,Karahalios A,et al.Age-related macular degeneration and mortality: the melbourne collaborative cohort Study[J].Eye,2017,31(9):1345~1357.
[2] Zhao R,Camino A,Wang J,et al.Automated drusen detection in dry age-related macular degeneration by multiple-depth, en face optical coherence tomography[J].Biomedical Optics Express,2017,8(11):5049~5064.
[3] 丁小燕,王志容,孙立梅.创造向未来:湿性AMD治疗进展及展望[J].中华实验眼科杂志,2019,37(1):63~68.
[4] 中华医学会眼科学分会眼底病学组.中国老年性黄斑变性临床诊断治疗路径[J].中华眼底病杂志,2013,29(4):343~355.
[5] 高欢欢,杜之渝,晏丕松,等.近视眼患者波前像差和对比敏感度相关分析[J].中华眼科杂志,2018,54(10):748~755.
[6] 杨玉青,安致稳,杨秀荣,等.益气养阴散结通络法联合针刺治疗湿性年龄相关性黄斑变性疗效探析[J].河北中医药学报,2019,34(2):23~25,47.
[7] 文小娟,蒋鹏飞,彭俊,等.蛴螬提取物对脉络膜新生血管中趋化因子受体3及其配体嗜酸性粒细胞趋化因子表达的影响[J].湖南中医药大学学报,2019,39(11):1326~1330.
[8] 朱祥祥,陈震,饶卓群,等.年龄相关性黄斑变性患者血浆miR-146a和miR-155水平检测及临床意义[J].临床眼科杂志,2019,27(3):231~234.
[9] 王爽,段素芳,牛秉轩,等.康柏西普对实验性脉络膜新生血管的作用机制研究[J].眼科新进展,2019,39(9):829~832.
[10] Tadayoni R,Waldstein SM,Boscia F,et al.Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion[J].Ophthalmology,2017,124(12):1778~1787.
[11] Minami Y,Nagaoka T,Ishibazawa A,et al.Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema[J].Bmc Ophthalmology,2017,17(1):28~33.
[12] 俞林笔,宋小莉,邢雁飞,等.雷珠单抗注射液联合复方血栓通胶囊对年龄相关性 黄斑变性患者临床疗效研究[J].河北医学,2019,25(5):800~804. |
|
|
|
2020, Vol. 26 
